Assessing Patient Access to Psoriasis Treatments in Central, South, and Eastern European Countries: Insights and Disparities?
Author(s)
jolanda M.A. koenders, MSc1, Sebastian G. Utz, PhD2, Sander MacLean, MSc3, Filip Dostál, MD, MA4.
1Msc, Takeda Netherlands B.V., Hoofddorp, Netherlands, 2Takeda Pharma AG, Zurich, Switzerland, 3Takeda Netherlands B.V., Hoofddorp, Netherlands, 4Takeda Pharmaceuticals Czech Republic s.r.o., Prague, Czech Republic.
1Msc, Takeda Netherlands B.V., Hoofddorp, Netherlands, 2Takeda Pharma AG, Zurich, Switzerland, 3Takeda Netherlands B.V., Hoofddorp, Netherlands, 4Takeda Pharmaceuticals Czech Republic s.r.o., Prague, Czech Republic.
OBJECTIVES: Map advanced treatment options available for moderate to severe plaque Psoriasis (PsO) patients in Central, South & Eastern European countries.
METHODS: We employed a structured desktop research approach between February and July 2024, leveraging local public data sources from 18 small-to-midsized Central, South & Eastern European countries, to understand the advanced PsO treatment options available for moderate to severe patients. Twenty advanced treatment options were considered, including anti-TNF, anti-IL-17, anti-IL-12-23/IL-23, PDE4i, TYK2i, independent of treatment line. Information on outcome-based contracts and reimbursement conditions was extracted and evaluated when publicly available.
RESULTS: From the 20 advanced treatment options considered, data from all 18 countries were available for 11 treatments. All countries had at least three advanced treatment options available (secukinumab, infliximab, adalimumab).
Nine countries offer 9 of the 11 treatment options (>80%), while three countries provide less than 4 of the 11 included treatment options (<40%). The remaining six countries have between 5-8 out of the 11 treatment options (40-80%) available.
Treatments with Market Approvals since 2019 onwards are not available in 7 of the 18 countries. Intravenous or subcutaneous treatment options are widely available (in 15 of the 18 countries), oral therapies are less available (8 out of the 18 countries), of which PDE4i is available in 8 out of 18 countries and TYK2i in 3 of the 18 countries at the time of mapping.
Two countries have implemented outcome-based contracts, although most countries utilize financial risk schemes to improve patient access.
CONCLUSIONS: Advanced treatment availability for moderate to severe psoriasis varies between the 18 countries. Treatments with market approvals from 2019 onwards are not widely available, especially oral options. Further research is required to understand the impact of the access disparities in patient outcomes.
METHODS: We employed a structured desktop research approach between February and July 2024, leveraging local public data sources from 18 small-to-midsized Central, South & Eastern European countries, to understand the advanced PsO treatment options available for moderate to severe patients. Twenty advanced treatment options were considered, including anti-TNF, anti-IL-17, anti-IL-12-23/IL-23, PDE4i, TYK2i, independent of treatment line. Information on outcome-based contracts and reimbursement conditions was extracted and evaluated when publicly available.
RESULTS: From the 20 advanced treatment options considered, data from all 18 countries were available for 11 treatments. All countries had at least three advanced treatment options available (secukinumab, infliximab, adalimumab).
Nine countries offer 9 of the 11 treatment options (>80%), while three countries provide less than 4 of the 11 included treatment options (<40%). The remaining six countries have between 5-8 out of the 11 treatment options (40-80%) available.
Treatments with Market Approvals since 2019 onwards are not available in 7 of the 18 countries. Intravenous or subcutaneous treatment options are widely available (in 15 of the 18 countries), oral therapies are less available (8 out of the 18 countries), of which PDE4i is available in 8 out of 18 countries and TYK2i in 3 of the 18 countries at the time of mapping.
Two countries have implemented outcome-based contracts, although most countries utilize financial risk schemes to improve patient access.
CONCLUSIONS: Advanced treatment availability for moderate to severe psoriasis varies between the 18 countries. Treatments with market approvals from 2019 onwards are not widely available, especially oral options. Further research is required to understand the impact of the access disparities in patient outcomes.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
RWD19
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
Biologics & Biosimilars, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)